Improving appropriateness of diagnosis and treatment of catheter associated urinary tract infection
This presentation is the property of its rightful owner.
Sponsored Links
1 / 32

January, 15, 2013 Presented by: Carolyn Gould, MD, MSCR Division of Healthcare Quality Promotion PowerPoint PPT Presentation


  • 99 Views
  • Uploaded on
  • Presentation posted in: General

Improving Appropriateness of Diagnosis and Treatment of Catheter-Associated Urinary Tract Infection. National Content Call. January, 15, 2013 Presented by: Carolyn Gould, MD, MSCR Division of Healthcare Quality Promotion Centers for Disease Control and Prevention. Disclosures.

Download Presentation

January, 15, 2013 Presented by: Carolyn Gould, MD, MSCR Division of Healthcare Quality Promotion

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Improving appropriateness of diagnosis and treatment of catheter associated urinary tract infection

Improving Appropriateness of Diagnosis and Treatment of Catheter-Associated Urinary Tract Infection

National Content Call

January, 15, 2013

Presented by:

Carolyn Gould, MD, MSCR

Division of Healthcare Quality Promotion

Centers for Disease Control and Prevention


Nothing to disclose

Disclosures

Nothing to Disclose


Outline

Outline

  • Discuss incidence and prevalence of asymptomatic bacteriuria (ASB) in different patient populations

  • Discuss symptomatic UTI criteria in patients with an indwelling urinary catheter

  • Define indications for screening and treatment of ASB

  • Discuss impact of inappropriate antimicrobial treatment


Case study

Case Study

  • 85 year old man with prostate cancer and chronic urinary catheter is transferred to hospital from nursing home after change in mental status and fall

  • Patient is afebrile with normal WBC count and no localizing symptoms

  • Urinalysis showed 15-20 WBC/hpf

  • Urine culture drawn from catheter grew multiple bacterial species

  • Patient treated with piperacillin-tazobactam for “urosepsis”


Case study continued

Case Study (continued)

  • On day #3, patient developed fever and elevated WBC count

  • Repeat urine culture sent from a new catheter grew MDR P. aeruginosa, resistant to pip-tazo

  • Antibiotics switched to imipenem

  • Patient developed acute abdominal pain and profuse, watery diarrhea

  • C. difficile toxin test was positive

  • Patient developed toxic megacolon and sepsis, was transferred to ICU, and subsequently died


Impact of cauti

Impact of CAUTI

  • Most common type of HAI

    > 30% of infections reported to NHSN

  • Up to 139,000 hospital-onset, symptomatic CAUTIs occur annually

    • Leading cause of secondary BSI with ~10% mortality

  • $131 million in excess direct medical costs

Hidron AI et al. ICHE 2008;29:996-1011Richards M, et al. Crit Care Med 1999;27:887-92

Wise M, et al. SHEA Abstract, Dallas, TX 2011

Scott R, et al. SHEA Abstract, Dallas, TX 2011


Pathogenesis of cauti

Source of microorganisms

Pathogenesis of CAUTI

Endogenous (meatal, rectal, or vaginal colonization)

Exogenous (contaminated hands of healthcare personnel during catheter insertion or manipulation of collecting system)

Figure from: Maki DG, Tambyah PA. Emerg Infect Dis 2001;7:1-6


Asymptomatic bacteriuria asb

Asymptomatic Bacteriuria (ASB)


Asymptomatic bacteriuria

Asymptomatic bacteriuria

  • Definition

    • Quantitative culture with ≥105 colony forming units/ml in an appropriately collected urine specimen without clinical signs/symptoms localizing to the urinary tract

  • Incidence of bacteriuria with indwelling urinary catheters

    • 3-10% per catheter-day

    • 26% of people with a catheter between 2-10 days

    • 100% of people with long-term (>30 d) catheters

  • Bacteriuria is rarely symptomatic


Idsa guidelines signs and symptoms compatible with cauti

IDSA Guidelines: Signs and symptoms compatible with CAUTI

  • new onset or worsening of fever, rigors, altered mental status, malaise, or lethargy with no other identified cause;

  • flank pain;

  • costovertebral angle tenderness;

  • acute hematuria;

  • pelvic discomfort;

  • In those whose catheters have been removed, dysuria, urgent or frequent urination, or suprapubic pain or tenderness

  • In patients with spinal cord injury, increased spasticity, autonomic dysreflexia, or sense of unease are also compatible with CAUTI

Hooton TM. Clin Infect Dis 2010;50


National healthcare safety network surveillance definitions for suti

National Healthcare Safety Network Surveillance Definitions for SUTI

http://www.cdc.gov/nhsn/PDFs/pscManual/7pscCAUTIcurrent.pdf


Prevalence of asb

Prevalence of ASB

Nicolle LE et al. Clin Infect Dis 2005; 40:643–54


Management of asb don t screen treat

Management of ASB: DON’T screen/ treat

Nicolle, LE. Int J Antimicrob Agents. 2006; 28S:S42-S48


Risks of antimicrobial use for asb

Risks of antimicrobial use for ASB

  • Selection for antimicrobial resistant pathogens

  • Adverse reactions to antimicrobial

  • C. difficile infection


When is it recommended to screen for and treat asb

When is it recommended to screen for and treat ASB?

  • In pregnant women

  • Before transurethral resection of the prostate and other urologic procedures where mucosal bleeding is anticipated

  • “No recommendation can be made for screening for or treatment of asymptomatic bacteriuria in renal transplant or other solid organ transplant recipients.”

Nicolle LE et al. Clin Infect Dis 2005; 40:643–54


No benefit of treating asb in long term catheterized patients

No benefit of treating ASB in long-term catheterized patients

  • Randomized, controlled trial of cephalexin use in asymptomatic long-term catheterized patients for susceptible organisms over 12-44 weeks

  • No differences in:

    • Weekly prevalence of bacteriuria (>98% in both groups)

    • Incidence or duration of bacteriuric episodes

    • Number of bacterial strains present

    • Febrile days

    • Catheter obstruction

  • 75% of bacteria in control group remained susceptible to cephalexin, compared to 36% in treatment group

Warren JW. JAMA 1982;248:454-8


No benefit of treating asb in diabetic women

No benefit of treating ASB in diabetic women

Harding GKM et al. N Engl J Med 2002;347:1576-83


No benefit of treating asymptomatic funguria

No benefit of treating asymptomatic funguria

  • Randomized, placebo-controlled trial of treatment of funguria in 316 asymptomatic or minimally symptomatic hospitalized patients

  • No differences in eradication of funguria 2 weeks after therapy for catheterized and non-catheterized patients

  • No invasive fungal infections or fungal-related deaths noted in either group

Sobel JP. Clin Infect Dis 2000;30:19-24


Is pyuria diagnostic

Is pyuria diagnostic?

Hooton TM. Clin Infect Dis 2010;50


Pyuria and asb

Pyuria and ASB

Nicolle LE et al. Clin Infect Dis 2005; 40:643–54


Pyuria in the elderly not useful

Pyuria in the elderly – not useful

Over 90% of older adults with positive urine cultures (bacteriuria) have pyuria

No evidence of poor clinical outcomes with high levels

If LE and Nitrite are both negative, then strongly predictive that a urinary tract infection is not present

Bottom line: Don’t get the test unless you know how to interpret AND plan on acting on the results

Nicolle LE. Infect Control Hosp Epidemiol 2001;22:167-175

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. 2009


Inappropriate treatment of catheter associated asb

Inappropriate treatment of catheter-associated ASB

  • Of 164 episodes of CA-ASB identified at one center over 3 months, 53 (32%) treated inappropriately with antibiotics

  • Independent risk factors for inappropriate treatment of ASB:

    • Predominant organism gram-negative

    • Higher urine WBC

    • Older age

  • Three patients developed C. difficile infection shortly after treatment for ASB

Cope M. Clin Infect Dis 2009;48:1182-8


January 15 2013 presented by carolyn gould md mscr division of healthcare quality promotion

“When antimicrobial agents are prescribed for the treatment of UTIs, not only the antimicrobial spectrum of the agent but also the potential ecological disturbances, including the risk of emergence of resistant strains, should be considered.”


Collateral damage

Collateral damage

  • Rampant use of fluoroquinolones (often used to treat diagnoses of community-associated pneumonia and UTIs) has contributed to the rise of the virulent, FQ-resistant epidemic NAP1/BI strain of C. difficile

    • Overprescribing for pneumonia driven by CMS process-of-care measure to treat patients within 4 hours of arriving to ED

  • Evaluation of CMS policy of non-payment for hospital-acquired CAUTI: no evidence of overtesting for UTI on admission or increased FQ use in 16 months after implementation of policy

Wachter RM et al. Ann Intern Med 2008;149:29

Morgan DJ et al. Clin Infect Dis 2012;55:923-9


Antimicrobial exposure and recurrent cdi

Antimicrobial exposure and recurrent CDI

  • Non-CDI antimicrobial therapy after an episode of CDI is common and is associated with a 3-fold increase in odds of recurrent disease

  • SHEA-IDSA CDI Guideline: “Discontinue therapy with the inciting antimicrobial agent(s) as soon as possible, as this may influence the risk of CDI recurrence”

Drekonja DM et al. Am J Med 2011;124:1081

Cohen SH et al. Infect Control Hosp Epidemiol 2010;31:431-55


Electronic memorandum reduces inappropriate treatment of asb and culture negative pyuria

Electronic memorandum reduces inappropriate treatment of ASB and culture-negative pyuria

  • 26% of patients with ASB/CNP inappropriately treated with antimicrobials

  • Educational memorandum placed in EMR reduced mean duration of antimicrobial use (2.2 days vs. 6.3 days, p < .001)

  • Adverse events from antimicrobials occurred in 3/30 controls (2 cases of CDI, 1 case of QT-interval prolongation)

Linares LA et al. Infect Control Hosp Epidemiol 2011;32:644-8


Strategies to reduce treatment of asb

Strategies to reduce treatment of ASB

  • Reduce inappropriate catheter use

  • Reduce inappropriate orders for urine cultures

    • Avoid reflex orders for UA/Ucx for “soft” indications (e.g., falls)

    • Difficult for clinicians to ignore a positive culture, regardless of symptoms

    • Pressure to treat – from patients, families, even surveyors (anecdotal reports from LTC)

Doernberg SB, V Dudas, KK Trivedi, ID Week 2012, Poster presentation


Patients with chronic catheters best practices for diagnosis and management

Patients with chronic catheters: best practices for diagnosis and management

  • Indwelling catheter in place for > 2 weeks at onset of CAUTI:

    • If still indicated, replace catheter and obtain urine culture from new catheter prior to initiation of antimicrobial therapy

    • If catheter not indicated, discontinue catheter and obtain culture of a voided midstream urine specimen prior to initiation of antimicrobial therapy

Hooton TM. Clin Infect Dis 2010;50


Summary

Summary

  • Screening for and treatment of ASB not indicated in patients with catheters (with few exceptions)

  • Presence of pyuria not diagnostic of CAUTI

    • Absence of pyuria is useful for ruling out CAUTI

  • Inappropriate treatment of ASB can lead to adverse events (especially CDI) and selection of antimicrobial resistant pathogens


Thank you questions

Thank you!Questions?

For more information, please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333

Telephone, 1-800-CDC-INFO (232-4636)/ TTY: 1-888-232-6348

Email: [email protected] Web: www.cdc.gov

The findings and conclusion in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and prevention.


Your feedback is important

Your Feedback is Important!

Please complete this session evaluation at the

conclusion of the presentation:

https://www.surveymonkey.com/s/CAUTICallEvaluation


Finding out more about joining cohort 6

Finding out more about joining Cohort 6

If you are interested in finding out more about Cohort 6, please click on the following link to enter your contact information https://www.surveymonkey.com/s/Cohort_6_Interest

or contact

Deb Bohr at 646-678-4280 or [email protected]


  • Login